Zimmer Biomet — Oct 30, 2024 release

  Page 4 of 23   Financial Guidance The Company is updating its full-year 2024 financial guidance to reduce and narrow its previous projected ranges for revenue growth and adjusted 1 diluted EPS: Projected Year Ending December 31, 2024     Previous Guidance Updated Guidance 2024 Reported Revenue Change 4.0% - 5.0% 3.5% - 4.0% Foreign Currency Exchange Impact (1.0)% (0.75)% 2024 Constant Currency Revenue Change 5.0% - 6.0% 4.25% - 4.75% Adjusted Diluted EPS (1) $8.00 - $8.15 $7.95 - $8.05   (1) This measure is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures” below, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure.   Conference Call The Company will conduct its third quarter investor conference call today, October 30, 2024, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be archived for replay following the conference call. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovat